Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug

Publisher： Bentham Science Publishers

E-ISSN： 2212-4055|10|6|497-508

ISSN： 1871-5281

Source： Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol.10, Iss.6, 2011-12, pp. : 497-508

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resistance to Anti-VEGF Agents

By  

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 51-64

Bentham Science Publishers

Access to resources Recommend Favorite

Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye

By Adis International Limited  

Drugs in R&D, Vol. 9, Iss. 4, 2008-01 ,pp. : 261-269

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 11, 2015-11 ,pp. : 641-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

By Stewart Michael W  

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Anti-VEGF Treatment of Corneal Neovascularization

By Keating Anne M.   Jacobs Deborah S.  

The Ocular Surface, Vol. 9, Iss. 4, 2011-10 ,pp. : 227-238

Ethis Communications

Access to resources Recommend Favorite